We reported pre‐clinical evidence for successful and prolonged tumor growth inhibition in HNC achieved by Cas9 mRNA and guide against SOX2 administered intratumorally via EGFR‐targeting LNPs. This evidence concerns the gene EGFR and neoplasm.